Dr. Reddy's Labs

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2020. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS). Q2 Performance Summary H1 Performance Summary   Rs. 4,897 Cr Rs. 9,314 Cr Revenue Revenue [Up: 11% QoQ; 2% YoY] [Up: 8% YoY]   53

Dr. Reddy's Q2 & H1 FY21 Financial Results

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the re-launch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC®, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's OTC Famotidine Tablets USP, 10 mg and

Dr. Reddy's announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, today announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India. This will be a multi-center and randomized controlled study, which will include safety and immunogenicity study. Earlier in September 2020,

Dr. Reddy's and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28th, 2020 after the Board Meeting. Summary of Events Event Date and Time Medium Release of financial results October 28th, after the Board Meeting Stock Exchange, Media, Company website, Business wire, Email Press meet presentation Will be available on the Company’s website Company’s website www.drred

Dr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further minimize environmental impact. The Company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 percent by 2030 from a FY2017-18 base year, which are in line with

Dr. Reddy’s Laboratories Joins Science Based Targets initiative (SBTi) and Sets 2030 GHG Emission Targets

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use. “We are pleased to launch this generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating our continued commitment to bring affordable generic medicines to market for patients,” says M

Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA). The Sensipar brand and generic market had U.S. sales of approximately $312 million MAT for the most recent twelve months endin

Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.Reddy’s”) today announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera® (dimethyl fumarate) Delayed-Release Capsules, approved by the U.S. Food and Drug Administration (USFDA). The Tecfidera® brand and generic market had U.S. sales of approximately $3.8

Dr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex® (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring this impor

Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

As of late, it has definitely been a great time to be an investor Dr. Reddy's Laboratories.

Dr. Reddy's Shares March Higher, Can It Continue?

DUBAI, UAE, Sept. 23, 2020 /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) and Dr. Reddy's Laboratories (NYSE: RDY) announced that the anti-viral drug Avigan® produced promising results in a single-blinded, placebo-controlled Phase 3 clinical study conducted in...

Avigan® Shows Promising Results in Treatment of COVID Patients in Japan

Bristol-Myers

Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.

Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers

Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr.

Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr.

Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr. Reddy’s

Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market

India's Dr. Reddy's Labs announced a pact to assist with clinical trials for Russia's Sputnik V coronavirus vaccine and to get 100 million doses of the vaccine; RDY stock rose to a buy zone.

India Pharma Inks Supply, Clinical Trials Pact For Russia's Sputnik Coronavirus Vaccine

The Russian Direct Investment Fund, or RDIF, Russia's sovereign wealth fund, and Indian drug company Dr.

Russia to provide Indian drug company Dr. Reddy's with 100 million doses of its COVID-19 vaccine

MOSCOW & HYDERABAD, India--(BUSINESS WIRE)--The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Dr. Reddy’s Laboratories Ltd.

RDIF and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India

Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market

AstraZeneca

Horizon Pharma

Eli Lilly

Repligen

Zoetis

The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.

6 of the Best Pharmaceutical Stocks to Buy Today

Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market

Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.

Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes

Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market

News for Dr. Reddy's Labs Stock (RDY)